INS and cancer: Several epidemiologic studies have correlated antihyperglycemic medication use with risk or outcomes of cancer, and have generally concluded that patients with type 2 diabetes treated with insulin and with sulfonylureas, which stimulate insulin secretion, have higher cancer incidence and mortality than those treated with metformin [218–223].